Astria Therapeutics to Present at Upcoming American Academy of Allergy, Asthma and Immunology and World Allergy Organization Joint Congress

Rhea-AI Summary

Astria Therapeutics (Nasdaq: ATXS), a biopharmaceutical company, announced its participation in the American Academy of Allergy, Asthma and Immunology (AAAAI) and World Allergy Organization (WAO) Joint Congress in San Diego, California on March 2, 2025.

Three posters will be presented:

• Markus Magerl, M.D., from Charité Universitätsmedizin Berlin, will present the design of the global Phase 3 trial of navenibart (poster 617) titled, “ALPHA-ORBIT – A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Navenibart in Adolescent and Adult Participants with Type 1 and Type 2 Hereditary Angioedema (HAE).”
• Joshua S. Jacobs, M.D., from Allergy and Asthma Clinical Research, Inc., will present attack severity reduction data from the ALPHA-STAR Phase 1b/2 trial of navenibart (poster 606) titled, “Treatment with Navenibart (STAR-0215) Reduces Attack Severity and Use of Rescue Medication in Patients with Hereditary Angioedema (HAE): Interim Results from the ALPHA-STAR Trial.”
• Chunxia Lily Zhao, Ph.D., from Astria Therapeutics, will present information on the profile of STAR-0310 (poster 697) titled, “Preclinical Data Supporting the Differentiated Profile of STAR-0310, a Novel OX40 Antagonistic Monoclonal Antibody.”

All presentations will occur in a poster session titled “Atopic Dermatitis, Contact Dermatitis, Urticaria, Angioedema” starting at 9:45am PST on March 2, 2025, in the Convention Center, Ground Level, Hall A.

BOSTON--(BUSINESS WIRE)-- Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that it will present three posters at the American Academy of Allergy, Asthma and Immunology (AAAAI) and World Allergy Organization (WAO) Joint Congress in San Diego, California on March 2, 2025.

• Markus Magerl, M.D., Professor of Dermatology and Allergy at the Charité Universitätsmedizin Berlin Institute of Allergology, will present the design of the global Phase 3 trial of navenibart in a presentation of poster number 617 titled, “ALPHA-ORBIT – A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Navenibart in Adolescent and Adult Participants with Type 1 and Type 2 Hereditary Angioedema (HAE).”
• Joshua S. Jacobs, M.D., Medical Director of Allergy and Asthma Clinical Research, Inc., will present attack severity reduction data from the ALPHA-STAR Phase 1b/2 trial of navenibart in a presentation of poster number 606 titled, “Treatment with Navenibart (STAR-0215) Reduces Attack Severity and Use of Rescue Medication in Patients with Hereditary Angioedema (HAE): Interim Results from the ALPHA-STAR Trial.”
• Chunxia Lily Zhao, Ph.D., Director of Antibody Discovery at Astria Therapeutics, will present information on the profile of STAR-0310 in poster number 697 titled, “Preclinical Data Supporting the Differentiated Profile of STAR-0310, a Novel OX40 Antagonistic Monoclonal Antibody.”

All three presentations will take place in a poster session titled “Atopic Dermatitis, Contact Dermatitis, Urticaria, Angioedema” beginning at 9:45am PST on March 2, 2025, in the Convention Center, Ground Level, Hall A.

About Astria Therapeutics:
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by allergic and immunologic diseases. Our lead program, navenibart (STAR-0215), is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Our second program, STAR-0310, is a monoclonal antibody OX40 antagonist in clinical development for the treatment of atopic dermatitis. Learn more about our company on our website, www.astriatx.com, or follow us on Instagram @AstriaTx and on Facebook and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250220927387/en/

Astria:

Investor Relations and Media:

Elizabeth Higgins

investors@astriatx.com

Source: Astria Therapeutics, Inc.

FAQ

What is the significance of Astria Therapeutics presenting at the AAAAI and WAO Joint Congress?

Astria Therapeutics will showcase important research findings and clinical trial data, highlighting their advancements in therapies for allergic and immunologic diseases.

When will Astria Therapeutics present at the AAAAI and WAO Joint Congress?

Astria Therapeutics will present on March 2, 2025, starting at 9:45am PST.

What will Markus Magerl present at the AAAAI and WAO Joint Congress?

Markus Magerl will present the design of the global Phase 3 trial of navenibart in a poster titled, “ALPHA-ORBIT – A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Navenibart in Adolescent and Adult Participants with Type 1 and Type 2 Hereditary Angioedema (HAE).”

What data will Joshua S. Jacobs present at the AAAAI and WAO Joint Congress?

Joshua S. Jacobs will present attack severity reduction data from the ALPHA-STAR Phase 1b/2 trial of navenibart in a poster titled, “Treatment with Navenibart (STAR-0215) Reduces Attack Severity and Use of Rescue Medication in Patients with Hereditary Angioedema (HAE): Interim Results from the ALPHA-STAR Trial.”

What will Chunxia Lily Zhao present at the AAAAI and WAO Joint Congress?

Chunxia Lily Zhao will present information on the profile of STAR-0310 in a poster titled, “Preclinical Data Supporting the Differentiated Profile of STAR-0310, a Novel OX40 Antagonistic Monoclonal Antibody.”

Where will the AAAAI and WAO Joint Congress presentations take place?

The presentations will take place in the Convention Center, Ground Level, Hall A, in San Diego, California.

What is the focus of the poster session where Astria Therapeutics will present?

The poster session is titled “Atopic Dermatitis, Contact Dermatitis, Urticaria, Angioedema.”